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Background: In femoropopliteal bypass surgery, the use of saphenous vein grafts is preferable, but synthetic grafts are
widely used above the knee. The objective of this meta-analysis was to assess the long-term patency of femoropopliteal
bypass grafts classified as above-knee polytetrafluoroethylene, above-knee saphenous vein, or below-knee saphenous vein.
Methods: Studies published from 1986 through 2004 were identified from electronic databases and reference lists; 73
articles contributed 1 or more series that used survival analysis, assessed femoropopliteal bypasses in one of the foregoing
configurations, reported a 1-year graft patency rate, and included at least 30 bypasses. The series with a predominance of
claudicant patients were included inmeta-analysis C, and the series in which critical ischemia predominated were included
in meta-analysis CI. Pooled survival curves of graft patency were constructed.
Results: In meta-analysis C, the pooled primary graft patency was 57.4% for above-knee polytetrafluoroethylene, 77.2%
for above-knee vein, and 64.8% for below-knee vein at 5 years; there was a significant difference between above-knee
grafts at 3, 4, and 5 years (P < .05). The corresponding pooled secondary graft patency was 73.2%, 80.1%, and 79.7%,
respectively (P > .05). In meta-analysis CI, the pooled primary graft patency was 48.3% for above-knee polytetrafluo-
roethylene, 69.4% for above-knee vein, and 68.9% for below-knee vein at 5 years; there was a significant difference
between above-knee grafts until 4 years (P< .05). The corresponding pooled secondary graft patency was 54.0%, 71.9%,
and 77.8%, respectively, with a significant difference between above-knee grafts at 2, 3, and 4 years (P < .05).
Conclusions: The great saphenous vein performs better than polytetrafluoroethylene in femoropopliteal bypass grafting
and should be used whenever possible. ( J Vasc Surg 2006;44:510-7.)The great saphenous vein is considered the most dura-
ble conduit for infrainguinal revascularization. A classic
randomized trial published in 1986 demonstrated the su-
periority of vein grafts in below-knee revascularization,
whereas the above-knee femoropopliteal polytetrafluoro-
ethylene bypass graft (AK-P) was equivalent to the above-
knee femoropopliteal saphenous vein bypass graft (AK-V)
for 18 months and was not significantly inferior thereafter.1
On the basis of these findings and data from uncontrolled
surgical series,2,3 it was argued that an AK-P should be
initially preferred to spare the saphenous vein for a future
bypass to a below-knee artery in the same limb. However, a
vein bypass subsequent to an AP has rarely been per-
formed,4,5 and such a vein-sparing approach has been
unrewarding.4,5 It is interesting to note that AK-Ps remain
in frequent use.6,7
Femoropopliteal revascularization deserves re-evaluation
for many reasons. First, four recent randomized trials 8 –11 have
shown the superiority of AK-V over AK-P in the first 12
months of follow-up. Second, it has been suggested that the
below-knee saphenous vein bypass graft (BK-V) must be
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510considered as the reference standard of infrainguinal bypass-
es.1,12–14 Third, patients with different symptoms must be
appraised separately, and standard types of graft patency
should be used. Finally, although there is continual develop-
ment of surgical skills,15 the competing endovascular alterna-
tives often improve at a much faster rate.16
Meta-analysis of uncontrolled surgical series can pro-
vide a reliable account of available data because these series
are frequent in the literature and often involve a large
number of patients.5 In this meta-analysis, we estimated the
long-term outcomes after femoropopliteal bypass per-
formed for claudication or critical ischemia and classified as
AK-P, AK-V, or BK-V.
MATERIALS AND METHODS
Study identification. TheMEDLINE electronic data-
base was searched by using the expression “femoropopliteal
bypass” and the terms “PTFE” and “saphenous” for the
period from January 1986 to December 2004. Two com-
plementary databases, EMBASE and LILACS, were
searched by using the term “femoropopliteal bypass.” The
abstracts of articles selected by title were read online to
reduce the number of articles for full-text examination.
Finally, additional titles were sought in the bibliographies
of the retrieved articles. Articles written in English, Ger-
man, French, Italian, Spanish, or Portuguese were exam-
ined.
Inclusion criteria. The articles included satisfied the
following requirements: (1) graft patency described with
life tables, survival curves, or suitable texts; (2) series of
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least some grafts; (4) a minimum of 30 bypasses in at least
1 series when an article described 2 or more series; and (5)
publication in 1986 or later. The series were included in
meta-analysis C when patients with claudication predomi-
nated and in meta-analysis CI when critical ischemia pre-
dominated.
Exclusion criteria. Various articles were excluded for
at least one of the following reasons: (1) clinical symptoms
not described, (2) predominance of blind segments of
popliteal artery, (3) predominance of composite bypass
grafts, (4) predominance of bypasses to the infrapopliteal
arteries, (5) repeat inclusion of bypasses, and (6) unreliable
or unattainable reconstruction of life tables from graphs or
texts. A total of 73 articles1,2,8 –12,14,17– 81 provided series
for meta-analysis (Appendix I, online only).
Data extraction. Two authors (C.E.P. and M.A.) ex-
tracted the data independently and resolved any disagree-
ment by discussion on several occasions. The outcome
measures of interest were primary graft patency and second-
ary graft patency.82 Of the 73 articles included, 54 de-
scribed primary or secondary patency, whereas the remain-
ing 19 articles reported primary assisted patency,
inappropriate primary patency, or simply cumulative pa-
tency. These nonstandard patencies were used subjectively
as primary patency for 2 AK-P series in meta-analysis C and
arbitrarily as secondary patency in 17 articles that contrib-
uted 14 (AK-P, n 5; AK-V, n 6; BK-V, n 3) series to
meta-analysis C and 13 (AK-P, n 2; AK-V, n 3; BK-V,
n  8) series to meta-analysis CI. The survival data were
extracted from life tables, survival curves that showed the
number of grafts at risk for at least some intervals, and plain
survival curves that omitted the number at risk. The survival
data were also extracted from the text and another source,
either a life table or a survival curve describing a different
outcome, and from the text alone.
Early mortality was investigated for the AK-V and
BK-V series combined and for the AK-P series. The effects
of runoff, the late use of a vein bypass after AK-Ps, and the
percentage of AK-Ps that became infected were also inves-
tigated.
Study quality. An ideal study should contain life tables
rather than graphs, the 1-month follow-up interval, a
5-year follow-up, losses to follow-up, no flat tails, and a
report of primary patency, secondary patency, and foot
preservation. Also important are a demographic profile
linked to survival analysis, the rates of previous operation
and tissue loss, a measurement of runoff, regimens of
postoperative anticoagulant therapy, reference to the use of
duplex scanning for graft surveillance, and data on further
bypasses. Each of the preceding items was graded 1 or 0, so
that a perfect study would score 15.
Statistical methods. Random-effects modeling explic-
itly recognizes that differences exist between outcomes at
different centers. This procedure combined monthly haz-
ard rates from single series of AK-Ps, AK-Vs, or BK-Vs to
yield a pooled estimate of patency for each graft configura-
tion and each month of follow-up. The product of succes-sive monthly pooled estimates of success then yielded a
pooled measure of cumulative patency for each type of
graft. Standard errors were calculated for the pooled esti-
mates, and within-study and between-study variances were
used to reduce the influence of study size on the pooled
estimates (Appendix II, online only). Statistical significance
(P  .05) was assessed for the differences between the
AK-P series and the other graft series at yearly intervals. The
statistical method used judges the significance of differ-
ences by examining the overlap between confidence inter-
vals, but it does not calculate P values.83 The pooled
estimates were displayed graphically for both meta-analyses
(Figs 1-4).
Sensitivity analysis. The effects of excluding series
that used nonstandard patencies or included heterogenous
clinical symptoms were investigated in both meta-analyses,
as also were the effects of excluding AK-P series with a score
of study quality higher than 9 for primary patency or higher
than 10 for secondary patency in meta-analysis C. A fixed-
Fig 1. Meta-analysis C of primary patency for above-knee femo-
ropopliteal polytetrafluoroethylene bypass grafts (AK-P; red line),
above-knee femoropopliteal saphenous vein bypass grafts (AK-V;
gray line), and below-knee saphenous vein bypass grafts (black
line). The vertical line indicates when AK-V surpassed AK-P.
Fig 2. Meta-analysis C of secondary patency for above-knee fem-
oropopliteal polytetrafluoroethylene bypass grafts (AK-P; red line),
above-knee femoropopliteal saphenous vein bypass grafts (AK-V;
gray line), and below-knee saphenous vein bypass grafts (black
line). The vertical line indicates when AK-V surpassed AK-P.effects model of meta-analysis, which estimates a single
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study variances, was considered. To adjust for flat tails, one
failure was added and then distributed in equal parts to the
months in the flat tail. This procedure seemed valid because
a null value for a sequence of monthly hazard rates at the
end of a survival curve, which determines the flat tail, likely
introduces bias. Changes in the pooled outcomes and in the
statistical inferences were examined. Funnel plots to detect
publication bias were not used because of the small number
of series in some meta-analyses.
RESULTS
Characteristics of the original studies. The study
design was retrospective in 49 articles and prospective in
the remaining 24. The latter included 6 randomized trials
comparing AK-Ps and AK-Vs and 18 nonrandomized stud-
ies. In the follow-up, the number of articles that contrib-
uted at least 1 series was 67 (92%) at 2 years, 65 (89%) at 3
Fig 3. Meta-analysis CI of primary patency for above-knee fem-
oropopliteal polytetrafluoroethylene bypass grafts (AK-P; red line),
above-knee femoropopliteal saphenous vein bypass grafts (AK-V;
gray line), and below-knee saphenous vein bypass grafts (black
line). The vertical line indicates when AK-V surpassed AK-P.
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Fig 4. Meta-analysis CI of secondary patency for above-knee
femoropopliteal polytetrafluoroethylene bypass grafts (AK-P; red
line), above-knee femoropopliteal saphenous vein bypass grafts
(AK-V; gray line), and below-knee saphenous vein bypass grafts
(black line). The vertical line indicates when AK-V surpassed
AK-P.years, 50 (68%) at 4 years, and 39 (53%) at 5 years. Withregard to the use of postoperative duplex scanning for graft
surveillance, 21 studies used this tool, either routinely
(AK-P, n  4; AK-V, n  3; BK-V, n  6) or selectively
(AK-P, n  6; AK-V, n  4; BK-V, n  6); 37 studies did
not use this tool; and 15 articles did not mention this
technology. The proportion of claudicant patients or an
interval containing this datum was often reported, but
other clinical variables were frequently omitted. AK-P series
scored the highest for quality in meta-analysis C (Table I).
The early mortality rate was 2.0% for 3405 procedures
in 30 vein graft series and was 1.9% for 3357 procedures in
23 AK-P series; it was 1.5% for 15 series in meta-analysis C
and 2.0% for 38 series in meta-analysis CI. The effects of
runoff on graft patency were described in 15 articles, but
good runoff was associated with a higher patency rate in
only 12 of these. The percentage of late vein bypasses after
an AK-P was 6.5% in 13 studies, but the rate of use of a
spared saphenous vein, described in only 6 of these studies,
was 5.1% after 648 AK-Ps. Graft infection occurred in 1.4%
of 1063 AK-Ps, but only 11 studies reported this event.
Graft patency in meta-analysis C. In a graphical
display of pooled survival curves for primary patency, AK-V
occupied the top position, whereas BK-V occupied the
lowest position until 27 months after bypass. Thereafter,
AK-P performed the worst (Fig 1). The difference in the
pooled primary patency between AK-P and AK-V was
significant at 3 years and beyond, but the difference be-
tween AK-P and BK-V was not significant at any interval
(Table II). When secondary patency was analyzed, AK-P,
AK-V, and BK-V were equivalent until 19 months after
bypass. Beyond this time, AK-P occupied the lowest posi-
tion (Fig 2), but the differences between AK-P and the vein
grafts were not significant (Table II).
When series that did not use standard patencies were
excluded, the difference between the pooled estimates of
primary patency at 5 years remained unchanged in AK-P vs
AK-V and increased by 7.7% in AK-P vs BK-V. In the
former comparison, the statistical significance became re-
stricted to one interval. When secondary patency was con-
sidered, there was an increase of 0.5% in AK-P vs AK-V,
with AK-V surpassing AK-P 4 months earlier, and a de-
crease of 1.1% in AK-P vs BK-V at 5 years, with no change
in the statistical inferences.
When bypasses for critical ischemia were excluded, the
5-year difference in AK-P vs AK-V decreased by 8.9% for
primary patency and increased by 6.9% for secondary pa-
tency, the 5-year difference in AK-P vs BK-V decreased by
2.7% for primary patency and 7.7% for secondary patency,
and the significant differences in AK-P vs AK-V were elim-
inated. When AK-P series with the highest scores of quality
were excluded, the 5-year pooled estimate decreased by
0.8% for primary patency and 0.9% for secondary patency.
Graft patency in meta-analysis CI. AK-P occupied
the lowest position from 5 months onward, whereas AK-V
and BK-V occupied similar upper positions for primary
patency (Fig 3). The difference in the pooled primary
patency between AK-P and AK-V was significant up to 4
years, whereas the difference between AK-P and BK-V was
AK-V
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patency was analyzed, AK-P occupied the lowest position,
whereas BK-V and AK-V performed equally well during the
entire follow-up (Fig 4). The difference in the pooled
secondary patency between AK-P and AK-V was significant
from 2 to 5 years, whereas the difference between AK-P and
BK-V was significant at all yearly intervals (Table II).
When series that did not use standard patencies were
excluded, the difference between the pooled estimates of
primary patency at 5 years increased by 2.0% in AK-P vs
AK-V and by 1.3% in AK-P vs BK-V, whereas for secondary
patency the corresponding increases were 7.6% and 1.4%.
Table I. Meta-analysis characteristics
Variable Graft Series/grafts
Meta-analysis C
Primary patency AK-P 20/1713
AK-V 9/580
BK-V 6/1338
Secondary patency AK-P 13/1187
AK-V 9/576
BK-V 9/1750
Meta-analysis CI
Primary patency AK-P 22/2431
AK-V 11/703
BK-V 17/2441
Secondary patency AK-P 13/2101
AK-V 9/663
BK-V 23/3194
AK-P, Above-knee femoropopliteal polytetrafluoroethylene bypass grafts;
knee saphenous vein bypass grafts.
Table II. Meta-analysis pooled estimates of graft patency
Variable 1 2
Meta-analysis C
Primary patency
AK-P 85.3(1.9) 77.4(2.0)
AK-V 87.5(4.4) 84.1(3.4)
BK-V 81.4(4.5) 76.0(3.9)
Secondary patency
AK-P 90.3(2.7) 85.3(3.1)
AK-V 89.8(2.2) 86.2(3.2)
BK-V 89.1(2.0) 86.0(2.7)
Meta-analysis CI
Primary patency
AK-P 76.3(1.9) 64.7(2.0)
AK-V 83.4(3.1)* 81.2(4.1)
BK-V 84.3(2.3)* 80.4(2.9)
Secondary patency
AK-P 80.1(1.6) 70.1(2.2)
AK-V 87.2(3.6) 83.7(3.2)
BK-V 87.4(2.0)* 83.5(2.3)
AK-P, Above-knee femoropopliteal polytetrafluoroethylene bypass grafts;
knee saphenous vein bypass grafts.
*P  .05 compared with AK-P series.There was no change in the statistical inferences.When bypasses for claudication were excluded, the
5-year difference in AK-P vs AK-V increased by 0.7% for
secondary patency, whereas the 5-year difference in AK-P
vs BK-V decreased by 1.3% for primary patency and in-
creased 5.0% for secondary patency, with few changes in the
statistical inferences.
Other sensitivity analyses. In meta-analysis C, the
fixed-effects model increased the pooled primary and sec-
ondary patency by 1.9% and 3.7% for AK-P, by 1.2% and
1.0% for AK-V, and by 0.8% and 1.9% for BK-V, respec-
tively, at 5 years. These changes favored AK-Ps slightly, but
the difference between AK-P and AK-V became significant
dard
ency
Year
(median)
Grafts for
claudication
(%)
Quality
(median)
0 1996 82-91 9
9 1998 86 7
4 1996 66 7
1 1997 82-93 10
6 1997 90 7
5 1995 71 8
8 1992 35-37 7
0 1995 13-15 7
4 1994 1-4 7
9 1992 28-30 9
4 1994 9-18 6
6 1992 9-15 7
, above-knee femoropopliteal saphenous vein bypass grafts; BK-V, below-
Years
3 4 5
70.9(2.4) 63.3(2.7) 57.4(3.3)
81.1(3.5)* 78.6(5.0)* 77.2(6.4)*
73.8(4.6) 68.3(6.5) 64.8(7.2)
83.9(4.3) 76.8(5.4) 73.2(6.3)
83.9(4.3) 82.3(5.6) 80.1(6.4)
84.2(4.9) 80.7(7.2) 79.7(7.7)
57.2(2.8) 51.8(3.0) 48.3(3.6)
76.6(5.0)* 72.6(5.4)* 69.4(9.1)
76.2(3.5)* 72.3(3.3)* 68.9(4.7)*
62.6(2.6) 57.4(3.1) 54.0(3.4)
79.1(5.1)* 76.9(6.3)* 71.9(8.7)
81.8(2.6)* 79.7(3.3)* 77.8(4.5)*
, above-knee femoropopliteal saphenous vein bypass grafts; BK-V, below-Stan
pat
2
1
1
1
1
1*
*
*
*
AK-Vfor primary patency also at 2 years as a consequence of
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decreased the 5-year pooled primary patency by 0.6% for
AK-P, 2.7% for AK-V, and 1.7% for BK-V. For secondary
patency, the corresponding decreases were 0.2%, 2.0%, and
0.8%, respectively. There was no change in the statistical
inferences.
In meta-analysis CI, the fixed-effects model increased
the pooled primary and secondary patency by 1.2% and
1.1% for AK-Ps, by 5.7% and 1.7% for AK-Vs, and by 1.1%
and 2.5% for BK-Vs, respectively, at 5 years. The difference
between AK-Vs and AK-Ps became significant for primary
and secondary patency at all yearly intervals. The adjust-
ments for flat tails decreased the 5-year pooled primary
patency by 0.6% for AK-P and BK-V and by 3.4% for AK-V.
The significance was abolished at 12 and 60 months and
was maintained at all other intervals in AK-P vs AK-V. The
corresponding adjustments for secondary patency in-
creased the 5-year pooled secondary patency by 0.3% for
AK-P and by 0.2% for BK-V but decreased this outcome by
1.6% for AK-V, with no change in the statistical inferences.
DISCUSSION
The small differences in primary and secondary patency
in AK-Vs in meta-analyses C and CI indicated that only a
few redo procedures were performed for this particular type
of bypass, probably because only three AK-V studies used
duplex scanning for graft surveillance routinely. In addi-
tion, graft patencies for AK-Ps were considerably lower in
meta-analysis CI than in meta-analysis C, but this was not
the case for AK-Vs and BK-Vs. Perhaps more severe ath-
erosclerosis in critical ischemia is more unfavorable to AK-P
grafts.
Meta-analysis C showed that AK-V tended to be supe-
rior to AK-P, and this became apparent for primary patency
at 5 months. The validity of the vein-sparing approach in
claudicant patients was denied, but this was less certain for
secondary patency (Fig 2), possibly because of the use of
standard patencies in only four of nine AK-V series (Table
I). Clearly, the small number of series and the lower pro-
portion of claudicant patients in the BK-V series biased the
comparison of AK-P vs BK-V, particularly for primary
patency, but the highest scores of study quality for AK-Ps
had no influence on the results. It is interesting to note that
AK-P series were published more frequently than AK-V
series; this reflects the preference for AK-Ps. Apart from a
sincere belief in the similarity between AK-P and AK-V and
in the value of not using the saphenous vein, other reasons
for such a preference include the reduced operative time
and, perhaps, the influence of commercial marketing activ-
ities.
In meta-analysis CI, which dealt with critical ischemia,
the difference between the vein graft series and the AK-P
series was readily apparent and significant at most yearly
intervals. The paucity of AK-V series was evident and
possibly reflected a more extensive popliteal involvement
above the knee than below the knee, a better opportunity
for using BK-V grafts in situ, or both. The validity of the
vein-sparing approach in terms of graft patency was deniedeven more emphatically than for claudicant patients. This
was so despite a larger proportion of claudicant patients in
the AK-P series. Because patients with critical ischemia
deserve the best operation on the first occasion,26 an AK-P
should not be recommended in the presence of a usable
saphenous vein.
The vein-sparing approach is also unwarranted for rea-
sons other than graft patency. Indeed, the mechanisms of
graft failure differ. There is more sudden thrombosis in
AK-P and greater myointimal hyperplasia in vein grafts36—
this is better identified by using a postoperative duplex
surveillance program—as well as a greater need for urgent
reoperation or a repeat bypass after AK-Ps.84 This analysis
showed that short-term graft failure was more frequent for
AK-Ps than previously believed and that, in the treatment
of such failure, thrombectomy or thrombolysis has been
used more often than a new bypass but has not been highly
successful.2,14,22,29,34 –37 Notably, the ultimate limb loss in
claudicant patients has been two times greater after AK-Ps
than after AK-Vs,56 and graft infection of AK-Ps may not be
as rare as the frequency of 1.4% suggested in this study.
Indeed, Pedersen et al85 reported a graft infection rate of
12% in 141 AK-Ps for claudication.
Apart from the inconveniences surrounding AK-Ps,
sparing a saphenous vein is unreasonable because the rate of
use of a saved vein in a late bypass has been consistently
low,9,11,18 –22,34 –37 alternative autologous veins are often
available for secondary bypass,86 and a failing vein graft can
be treated with no further bypass.64,65 Hence, a smaller
number of graft failures, together with less severe conse-
quences of failed or complicated grafts, strengthen the
argument for the use of a saphenous vein in primary femo-
ropopliteal bypass.
Despite traditional preferences, uncertainty remains
about the best synthetic graft for above-knee bypasses and
the best configuration of vein grafts. Umbilical cord vein
grafts performed significantly better than AK-Ps in two
randomized trials,8,22 whereas Johansen and Watson15 re-
ported a superb 5-year cumulative primary patency rate of
84% for Dacron grafts (DuPont, Wilmington, Del) in a
cohort of 92 good-risk patients with claudication. Only a
few reports have suggested BK-V as the standard femoro-
popliteal bypass with the reversed saphenous vein,3,12,13
but BK-V has emerged as the best-suited anatomic config-
uration for in situ saphenous vein bypasses.14 The current
meta-analyses failed to show any reliable trend favoring
AK-Vs or BK-Vs but revealed that BK-Vs were performed
much more often than AK-Vs.
The superiority of vein grafts over angioplasty has not
been challenged in the treatment of femoropopliteal dis-
ease for claudication, but the same cannot be said for
synthetic grafts. Hunink et al87 determined a 5-year pri-
mary patency of 73% for vein grafts, 49% for polytetrafluo-
roethylene grafts, and 45% for angioplasty. In the treatment
of critical limb ischemia, there seems to be even less room
for AK-Ps. Indeed, another meta-analysis yielded a 3-year
pooled primary patency of 63%,16 whereas the correspond-
ing figure for AK-Ps was 62.6% in meta-analysis CI de-
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between an endovascular procedure and a synthetic graft
for suitable patients who have no usable vein.
Early mortality rates were described infrequently in the
studies examined. These rates, which cannot be ignored by
the surgeon, must be disclosed to the patient and are useful
in choosing between angioplasty and open bypass, but not
in choosing between an AK-P and a vein graft, because the
same rate occurs in AK-P and vein graft series. Because
AK-Ps and vein grafts have the same risk of early mortality
and because in meta-analysis CI AK-V and BK-V per-
formed significantly better than AK-Ps at 1 year, an AK-P
should not be used in patients with critical ischemia simply
because of a short life expectancy. Meta-analysis C did not
show significant differences between AK-P and vein graft
series in the early years of follow-up, but a short life expect-
ancy is an uncommon feature of claudicant patients.
In strong support of the inferences from this meta-
analysis, the study design was compatible with real life;
allowed an adequate sampling of hypothetical populations
of studies; reduced the confounding effect of clinical symp-
toms, graft material, and level of distal anastomosis; and
provided pooled survival curves that consistently decreased
over time. Furthermore, the studies reviewed in this meta-
analysis adopted similar outcomes, used data of acceptable
quality, and reported high response rates. Finally, sensitiv-
ity analysis showed that outcomes were robust in favor of
vein grafts.
Most of the limitations in this study were attributable
to the nonrestrictive criteria of inclusion that were
adopted and to the imperfect state of the existing litera-
ture. Articles were often retrospective, did not separate
clinical symptoms appropriately, reported outcomes se-
lectively, described AK-Vs and BK-Vs together, did not
use standard patencies, described a short follow-up time,
omitted losses to follow-up and their effect on graft
patency, showed a flat tail in the survival curve, or did not
mention the postoperative use of duplex scans. Not all of
these problems could be handled satisfactorily in this
analysis.
This meta-analysis provided observational evidence on
femoropopliteal bypass surgery for which the randomized
evidence is scarce. AK-Vs and BK-Vs performed better than
AK-Ps and should be used whenever possible to reduce the
gap between the best practice and the true practice.6 How-
ever, the absence of a suitable saphenous vein remains an
acceptable indication for an AK-P, at least until the poten-
tials of other alternatives are fully established.
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Author Year
AK-P AK-V BK-V
Meta-
analysisPP SP PP SP PP SP
Aalders25 1992 *      C
AbuRahma10 1999 *  * *   C
Achermann30 1998       C
Allen19 1996 *    * * C
Archie26 1994 *  *  *  CI
Ballotta11 2003  *     C
Bandyk65 1987     * * CI
Bastounis46 1999       CI
Blankensteijn56 1988   * *   C
Böhmig66 1995       C/CI
Bourke48 1992     * * CI
Budd33 1990 *  *  *  CI
Chapleau60 1991       C
Chikiar68 2003 *  *    CI
Curi41 2002 * * * *   CI
D’Addato55 1992       CI
Davies34 1991 *      CI
Deutsch69 1999 *      C
El-Kayali37 2003 *      CI
Enzler63 1991      * CI
Erasmi27 1996       C
Falco70 1995      * CI
Florenes59 1993      * C
Franks71 1992       C/CI
Green28 2000       C
Griffiths42 2004       CI
Gupta24 1991 *      CI
Hagmüller72 1990       C/CI
Hamann73 1998 *  *    C/CI
Harris74 1987       CI
Jamsen75 2001     *  CI
Jensen52 1992       CI
John36 1993       CI
Johnson8 2000    *   C/CI
Kavanagh21 1998       CI
Kent44 1988       C
Klinkert9 2003   * *   C
Kretschmer76 1992       CI
Kumar43 1995       C
Lang77 2001       CI
Laurendeau35 1989       CI
Lawson47 1999     * * C
Lu40 2002 *      C
Lundell64 1995       CI
Macaulay80 1996     * * CI
Maini51 1996     * * CI
McLoughlin81 1989 *      CI
Mills50 1991      * CI
Miyazaki17 2002       C
Najmaldin61 1987      * CI
Neale31 1994    *   CI
Okadome67 1990       C
Parker57 1988      * CI
Patterson20 1990       CI
Plecha45 1996     * * CI
Post38 2001 *      C
Prendiville2 1990 *      C/CI
Rafferty23 1987       C/CI
Raptis18 1995       C
Rosenthal22 1990       C
Sala32 2003       CI
Schulman49 1987       CI
Stierli78 2001   *    C
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Author Year
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Meta-
analysisPP SP PP SP PP SP
Stonebridge54 1997       CI
Strayhorn62 1988       CI
Taylor12 1990      * CI
Veith1 1986    *  * CI
Veterans
Administration53
1988       CI
Watelet58 1987    *   CI
Whittemore29 1989       C/CI
Wilson39 1995 *  *    CI
Woratyla14 1997       C/CI
Z’graggen79 1990  *  *   CI
AK-P, Above-knee femoropopliteal polytetrafluoroethylene bypass grafts; AK-V, above-knee femoropopliteal saphenous vein bypass grafts; BK-V, below-
knee saphenous vein bypass grafts; PP, primary patency; SP, secondary patency; , not included in meta-analysis; , included in meta-analysis.
*Flat tail present.
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The strategy. We constructed a strategy to combine
survival data because different grids of time intervals had
been used in the series reviewed. In the first step, we
redistributed in equal quantities at 1-month intervals grafts
censored at intervals greater than 1 month. Next, we ob-
tained the numbers of failed grafts for intervals of 1 month
by using the grafts at risk at the start of an interval, the
redistributed censored units, and the interval hazard rates.
We then calculated the Kaplan-Meier success rates for each
series and each month of follow-up and used these rates as
treatment effects. This approach assumed constant hazard
rates within long time intervals and the midpoint of such
intervals as the survival time for censored units, as is usual in
actuarial survival analysis.
In the second step, we calculated a within-series vari-
ance (s2) for each monthly success rate in each series; next,
we calculated a between-series variance (2) for each
month. To obtain pooled measures of treatment effect for
eachmonth of follow-up, we used in the third step random-
effects modeling, which assumes that included studies are a
random sample of the universe of studies. Finally, the
product of successive monthly pooled measures of treat-
ment effect allowed us to obtain pooled measures of cumu-
lative success and to calculate approximate standard errors.
The statistical problem. Because this meta-analysis
dealt with uncontrolled studies, our primary problem was
one of parameter estimation, not hypothesis testing. Con-
sequently, we estimated pooled measures and calculated
their standard errors for AK-P, AK-V, and BK-V at yearly
intervals. From these quantities, it was possible to calculate
the overlap of two 95% confidence intervals and use this
result to declare statistical significance (P  .05) or negate
it (P .05) for the comparison of AK-P vs AK-V and AK-P
vs BK-V at yearly intervals.86
Interval success rate. For each series i and each month
j of follow-up, an interval success rate, ij, was determined
as follows:
ij 1 fij ⁄ nij ,
where f is the number of failed grafts and n is the numberij ij
of grafts at risk.Within-series variance. The within-series variance,
sij
2, was obtained as follows:
s ij
2  nij nij 22 ⁄ fij 1nij fij 1.
Between-series variance. For each month j, the between-
series variance, j
2, was calculated as follows:
j
2niimj2 ⁄ kj 1 ⁄ kj ni ,
where, in the target month j, i is the success rate in study
i, mj is the average for i, ni is the number of units at risk,
and kj is the number of series available.
Weighting and combining the ij. Let wij be the
weight attributed to each ij. When using random-effects
modeling, it follows that
Wij 1 ⁄ sij2  j2.
A summary effect estimate, Lj, was obtained for interval
graft patency in month j as follows:
Ljiwi ⁄ wi ,
where i is the success rate in the target month j and wi is
the weight attributed to i.
Such estimators Ljwill be consistent and approximately
normal and are derived on the basis of the fact that the
estimators for each series are approximately normal with an
estimable variance. Finally, the product of successive Lj
yielded Gj, the summary estimate for cumulated success at
month j.
Variance and confidence interval for Gj. After they
were properly corrected, Kaplan-Meier estimates and their
respective variances in the single series were used to obtain
the variance of Gj. This was performed by again using
random-effects modeling in a way similar to that of obtain-
ing Lj. The difference was that Peto within-series variances
in study i at month j and j
2 were summed up to weigh the
Kaplan-Meier estimates at month j. A summary Kaplan-
Meier estimate, Kj, and its variance, V{Kj}, were thus ob-
tained for month j. Because Kj and Gj differed a little, the
variance of Gj, V{Gj}, was obtained as follows:
VGj VKjLj1 Lj
2 ⁄ Kj 1 Kj2.The standard error for Gj was the square root of V{Gj}.
